A Phase 3 interventional study of Catheter ablation in Ischemic Stroke and Atrial Fibrillation Non-Rheumatic, sponsored by Nippon Medical School. Active, not recruiting at 46 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-11-15.
Sponsored by Nippon Medical School · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Ischemic Stroke with a site in Japan — 7 open to participants now, 11 under way, 3 of them phase 3. Ischemic Stroke · Japan.
Among the 43 studies in Ischemic Stroke with a site in Japan, this one is the 19th largest by enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2018, is one of 8 in phase 3, reaches primary completion later than 1 of the 10 other live ones, and was the 25th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →7 of the 43 studies in Ischemic Stroke with a site in Japan are open now. Recruiting first, the newest first:
Takeda · Sites in Japan, United States, Belgium and 7 more countries
Ages 18+
Astellas Pharma Inc · Sites in Japan
Ages 18–80
Osaka University · Sites in Japan
Hyogo Medical University · Sites in Japan, Thailand, Vietnam
Ages 18–84
Nippon Medical School · Sites in Japan
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 20 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 10 · Phase 4 5
First in 2004; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 251 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 270 across the 35 interventional studies, 650 across the 8 observational. Of the 28 that completed or were terminated, 11 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 43 have an industry lead sponsor. The 10 most frequent:
Nippon Medical School is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Nippon Medical School has 2 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
2 of the studies in Ischemic Stroke with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02251665National Cerebral and Cardiovascular Center, JapanNational Cerebral and Cardiovascular Center (NCVC) Stroke Registry | 2027-03 |
| NCT07819526Osaka UniversityAcute Ischemic Stroke in Patients With Active Cancer | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies in Ischemic Stroke with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Catheter ablation (CA) has been reported to reduce risk of stroke in patients with nonvalvular atrial fibrillation (NVAF) in retrospective studies, but risk and benefit of CA has not been well elucidated in NVAF with recent cerebral infarction in prospective randomized trials.
In patients with NVAF, stroke is an independent risk factor for a subsequent cerebral infarction. Although anticoagulant therapy can effectively reduce thromboembolic events, the reported annual recurrence rate in NVAF and previous stroke patients in the "real-world" is not low even with appropriate antithrombotic treatment; 8.6% in patients with "guideline adherent" antithrombotic therapy and around 5% in patients treated with anticoagulant therapy. NVAF and recent stroke is high-risk population for stroke recurrence even with anticoagulant therapy, and developing optimal secondary prevention strategy is an urgent task.
Catheter ablation (CA) is now widely used to treat symptoms related to NVAF. Some retrospective studies showed a beneficial effect of CA for stroke prevention using age-/sex-matching or propensity-score matching. Moreover, CA have a potential to improve survival or prevent heart failure development in patients with AF. However, the effect of CA for secondary stroke prevention or impact of CA for NVAF patients with recent ischemic stroke for survival or developing heart failure has not been evaluated in a prospective randomized trial. Therefore, in the present study, we intend to compare two groups of patients with NVAF with a history of cerebral infarction: a group receiving standard medical therapy (control group) and a group receiving standard medical therapy plus CA (CA group).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The preferred anticoagulant is edoxaban. Antiarrhythmic drugs are administered as needed for the patient by well-trained cardiologists.
Catheter ablation (CA) should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required. For conducting CA by a trained and experienced cardiologist, only institutions in which performed \>100 CA annually were participated in the present study in principle.
Procedure: Catheter ablation
CA should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required.
Composite of recurrence of cerebral infarction, systemic embolism, all-cause death, hospitalization for heart failure.
Composite of recurrence of cerebral infarction, systemic embolism, all-cause death, hospitalization for heart failure.
Time frame: Up to 6 years
Recurrence of cerebral infarction
Recurrence of cerebral infarction
Time frame: Up to 6 years
Systemic embolism
Symptomatic systemic embolism to other regions than brain, e.g. peripheral or visceral arteries
Time frame: Up to 6 years
All-cause death
All-cause death
Time frame: Up to 6 years
Cardiovascular death
Cardiovascular death
Time frame: Up to 6 years
Hospitalization for heart failure
Hospitalization for heart failure
Time frame: Up to 6 years
Any bleeding
Any bleeding
Time frame: Up to 6 years
Intracranial hemorrhage
Intracranial hemorrhage
Time frame: Up to 6 years
Composite events
all-cause death, onset of stroke, systemic embolism, hospitalization for heart failure, and serious adverse event caused by CA
Time frame: Up to 6 years
The rate of and related factors to discontinuation of Edoxaban
The rate of and related factors to discontinuation of Edoxaban
Time frame: Up to 6 years
Recurrence of cerebral infarction in patients with or without discontinuation of Edoxaban
Recurrence of cerebral infarction in patients with or without discontinuation of Edoxaban
Time frame: Up to 6 years
Incidence of treatment-emergent adverse events (safety and tolerability)
Incidence of treatment-emergent adverse events (safety and tolerability)
Time frame: Within 1 month after CA
Incidence of all adverse events, not restricted to CA maneuver-related adverse events
Incidence of all adverse events, not restricted to CA maneuver-related adverse events
Time frame: Within 1 month after CA
Drug reaction to edoxaban
Drug reaction to edoxaban
Time frame: Up to 6 years
Plan to share: Undecided
Started Apr 2018 (actual). Primary completion is estimated for Mar 2026, 95 months after the start.
Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 95 months is above that.
Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nippon Medical School